Disclosure of the mechanisms of the medical preventional effect of fucoidan in the composition of food systems

It is very promising to study the molecular mechanism and basis of the action of fucoidan in food systems for the prevention of inflammatory bowel diseases (IBD) using network pharmacology as a new paradigm for drug design and molecular docking technology. Our results offer a theoretical framework for future clinical investigations. The GeneCards and OMIM network databases were used to seek and screen the targets for IBD activity in the treatment of gastric cancer lesions. The string data platform was used to create the protein interoperability network of fucoidan for the treatment of IBD, whereas Cytoscape 3.9.1 was used to create the compound-target network. Topological analysis was used to identify the main target. Finally, the drug-disease intersection target was analysed using enrichment and biological pathways. A total of 81 component targets were gathered, and using network topology and protein interoperability network analysis, 6758 targets for IBD were found, along with another 301 essential core targets. The key targets were evaluated to include STAT3, ESR1, BCL2, and AKT1, among others. 173 signaling pathways, including pathway in cancer, metabolic pathway, Neuroactive ligand-receptor interaction, and PI3K-Akt signaling pathway were screened from KEGG and GO functional enrichment analysis. Best binding of -6.5 kcal/mol with AKT1 was obtained from additional docking studies with fucoidan. Fucoidan acts on targets such as AKT1, ESR1, STAT3, and BCL2, as well as important inflammatory, immunological, and gastric cancer pathways, and can be utilised to prevent and manage IBD.